Please login to the form below

Not currently logged in
Email:
Password:

Principles of joint NHS/pharmaceutical industry initiatives

Principles of joint NHS/pharmaceutical industry initiatives
  • All joint working between the pharmaceutical industry and the NHS must be for the benefits of patients
  • The interests of individual patients must be protected
  • Clinical aspects of care, including the development of guidelines and protocols, should be under local/national NHS control, and industry input is legitimate and offers potential benefits to patients and NHS organisations
  • Long-term strategic partnership is the desired outcome, but work should proceed on a project by project basis
  • All patient identifiers should be removed from data to respect and preserve patient confidentiality in line with the Data Protection Act
  • Reports or information pertaining to the project/agreement should not be used or published without explicit permission given by all partners entering the agreement
  • Joint working should not be seen as an endorsement or promotion of a specific medicine or technology
  • Joint working should not undermine or conflict with the ethical requirements of any healthcare professional, including the duty of the clinicians to provide whatever treatment they consider clinically appropriate
  • Pharmaceutical companies must comply with the ABPI Code of Practice for the Pharmaceutical Industry at all times
  • All NHS employed staff must comply with NHS (and relevant professional bodies) codes of conduct at all times
  • Pharmaceutical company size (turnover) should not dictate involvement with the NHS
  • If joint working involves research, then best research practice should be applied and consultation with the relevant Local Research Ethics Committee should be sought.

Source: ABPI: NHS and Pharmaceutical Industry Working Together for Patients, 2005

2nd September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics